Institutions' substantial holdings in Revance Therapeutics implies that they have significant influence over the company's share price 50% of the business is held by the top 9 shareholders ...

Salim Syed, an analyst from Mizuho Securities, maintained the Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The associated price target remains the same with $99.00. Salim Syed ...

The new standards — on everything from carbon pollution to wastewater — are the last major pieces of Biden’s push to clean up the power sector. The Biden administration will release four ...

for intravitreal pegcetacoplan for geographic atrophy to the last phase of the initial assessment (day 180). The procedure is expected to be led by the original rapporteurs, and EMA has stated ...

Gov. Michelle Lujan Grisham, a vocal proponent of the 180-day rule, lambasted the suit in a written statement, saying "This is another pathetic attempt to avoid accountability for delivering a ...

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP ...

The new standards — on everything from carbon pollution to wastewater — are the last major pieces of Biden’s push to clean up the power sector. The Biden administration will release four ...

House Speaker Pat Grassley (R-New Hartford) on Iowa Press set. (Photo courtesy of Iowa PBS.) Speaker Pat Grassley says if Republicans retain control of the Iowa House after the November election ...

BETHESDA, Md. - Gain Therapeutics, Inc. (NASDAQ:GANX), a biotechnology company focused on developing allosteric small molecule therapies, has announced positive results from its Phase 1 clinical ...

In a recent move that signals confidence, Joel Lewis, the President and CEO of Galectin Therapeutics Inc. (NASDAQ:GALT), has purchased additional shares of the company. On April 24, Lewis acquired ...